Peritonitis: Clinical Trials

8 trials for Peritonitis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed, 1 recruiting, 1 terminated. 8 Phase 2, 2 Phase 3, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 28Completed 6, Recruiting 1, Terminated 1
Phase 32Completed 2
Phase 11Completed 1

Follow Peritonitis: new trials by email Literature Review of Peritonitis trials Research Report on Peritonitis

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Pharmacokinetics of Meropenem and Aztreonam After Intraperitoneal Administration Via Cycler-therapy in APD Patients Without Peritonitis
Meropenem 1000 mg, Aztreonam 2000 mg, automated peritoneal dialysis with following long time dwell - Peritoneal Dialysis Associated Peritonitis, Peritoneal Dialysis (PD)
Phase 2 / Phase 3CompletedKarl Landsteiner Insitute for Nephrology and Haemato-Oncology122021-08-312025-08-11
Prospective, Randomized Trial of Personalized Medicine With Pentaglobin® After Surgical Infectious Source Control in Patients With Peritonitis
Pentaglobin®/Standard of Care - Peritonitis, Sepsis
Phase 2RecruitingRWTH Aachen University2002017-11-202026-06-11
The Effects of Oral Vitamin D Supplementation on the Prevention of Peritoneal Dialysis-related Peritonitis
Cholecalciferol (2000iu qd), Routine therapy for PD - Peritoneal Dialysis-associated Peritonitis, Vitamin D Deficiency
Phase 2CompletedPeking University First Hospital602017-09-302021-08-18
Comparative Evaluation of Intra-operative Peritoneal Lavage With Super Oxidized Solution and Normal Saline in Peritonitis Cases
Super Oxidized Solution in group I - Peritonitis
Phase 2CompletedMaharishi Markendeswar University (Deemed to be University)2902014-12-012016-08-30
GSK2251052 in the Treatment of Complicated Intra-abdominal Infections
Drug: GSK2251052, Meropenem, Placebo - Infections, Intestinal
Phase 2TerminatedGlaxoSmithKline152011-10-032017-11-29
Protective Effect of N-acetylcysteine Against From Ototoxicity
N-acetylcysteine - Hearing Loss, Extreme
Phase 2 / Phase 3CompletedTC Erciyes University602010-06-012011-11-16
Ascending Single Dose Study of Rhu-pGelsolin in Patients With Decreased Gelsolin Levels
rhu-pGelsolin, Placebo - Low Gelsolin, Trauma
Phase 1 / Phase 2CompletedCritical Biologics Corporation402008-03-012010-09-29
Prevention of Drug Induced Ototoxicity in Peritoneal Dialysis Patients by N-Acetylcysteine
N-acetylcysteine - Drug-induced Ototoxicity in Peritoneal Dialysis Patients
Phase 2CompletedTC Erciyes University602008-02-012010-05-27

Narrower conditions

Infections (3)  ·  Ototoxicity (2)  ·  Sepsis (2)  ·  Abscess (1)  ·  Burns (1)  ·  Deafness (1)  ·  Intraabdominal Infections (1)  ·  Kidney Failure, Chronic (1)  ·  Meretoja syndrome (1)  ·  Pneumonia (1)  ·  Shock, Septic (1)  ·  Systemic Inflammatory Response Syndrome (1)  ·  Vitamin D Deficiency (1)  ·  Wounds and Injuries (1)

Broader conditions

Digestive System Diseases (8)  ·  Peritoneal Diseases (8)  ·  Intraabdominal Infections (7)  ·  Pathologic Processes (6)  ·  Pathological Conditions, Signs and Symptoms (6)  ·  Infections (5)  ·  Inflammation (3)  ·  Chemically-Induced Disorders (2)  ·  Drug-Related Side Effects and Adverse Reactions (2)  ·  Ear Diseases (2)  ·  Otorhinolaryngologic Diseases (2)  ·  Radiation Injuries (2)  ·  Shock (2)  ·  Wounds and Injuries (2)  ·  Avitaminosis (1)

Interventions

Acetylcysteine (2)  ·  Meropenem (2)  ·  3-(aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1,3-dihydro-2,1-benzoxaborole (1)  ·  Aztreonam (1)  ·  Cholecalciferol (1)  ·  Saline Solution (1)

Sponsors

TC Erciyes University (2)  ·  Critical Biologics Corporation (1)  ·  GlaxoSmithKline (1)  ·  Karl Landsteiner Insitute for Nephrology and Haemato-Oncology (1)  ·  Maharishi Markendeswar University (Deemed to be University) (1)  ·  Peking University First Hospital (1)  ·  RWTH Aachen University (1)

Countries

Austria (2)  ·  Turkey (Türkiye) (2)  ·  Canada (1)  ·  China (1)  ·  Czechia (1)  ·  France (1)  ·  Germany (1)  ·  Hong Kong (1)  ·  Italy (1)  ·  Russia (1)  ·  Spain (1)  ·  United States (1)

Top investigators

Bulent Tokgoz, MD (1)  ·  Gernot Marx, Univ.-Prof. (1)  ·  Ismail Kocyigit, MD (1)  ·  Jie Dong (1)  ·  Martin F Wiesholzer, MD (1)  ·  Richard C Straube, MD (1)  ·  Selene Tam, PhD (1)  ·  Wai M Chan, MBBS (1)

Results publications

PMID 21551083, PMID 25073872, PMID 30832742, PMID 31779675

NIH funding

2016 (1)